The productivity crisis in pharmaceutical R&D

Griliches, Z. Productivity, R&D, and the data constraint. Amer. Econ. Rev. 84, 1–23 (1994).

Kortum, S. Equilibrium R&D and the patent–R&D ratio: US evidence. Amer. Econ. Rev. 83, 450–457 (1993).

Kortum, S. Research, patenting, and technological change. Econometrica 65, 1389–1419 (1997).

Lanjouw, J. & Schankerman, M. Patent quality and research productivity: measuring innovation with multiple indicators. Econ. J. 114, 441–465 (2004).

Jones, B. The burden of knowledge and the 'death of the reinassance man': is innovation getting harder? Rev. Econ. Stat. 76, 283–317 (2009). A parsimonious explanation for the increase in specialization and teamwork in pharmaceutical R&D.

Everson, R. Patents, R&D and invention potential: international evidence. Amer. Econ. Rev. 83, 463–468 (1993).

Segerstrom, P. Endogenous growth without scale effects. Amer. Econ. Rev. 88, 1290–1310 (1998).

Drews, J. In Quest of Tomorrow's Medicines 1–272 (Springer, Basel, 1998).

Cockburn, I. M. in Innovation Policy and the Economy Vol. 7 Ch. 1 (eds Jaffe, A. B., Lerner, J. & Stern, S.) 1–32 (The MIT Press, 2007). A critical assessment of the productivity crisis in pharmaceutical R&D.

Orsenigo, L., Pammolli, F. & Riccaboni, M. Technological change and network dynamics: lessons from the pharmaceutical industry. Res. Policy 30, 485–508 (2001).

Booth, B. & Zemmel, R. Prospects for productivity. Nature Rev. Drug Discov. 3, 451–456 (2004).

Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203–214 (2010).

DiMasi, J., Hansen, R. & Grabowski, H. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).

Munos, B. Lessons from 60 years of pharmaceutical innovation. Nature Rev. Drug Discov. 8, 959–968 (2009).

Mervis, J. Productivity counts — but the definition is key. Science 309, 726–726 (2005).

Pammolli, F. & Riccaboni, M. Innovation and Industrial Leadership: Lessons from Pharmaceuticals (Center for Transatlantic Relations, 2008). This book contains an in-depth analysis of pharmaceutical productivity based on the PhID.

David, E., Tramontin, T. & Zemmel, R. Pharmaceutical R&D: the road to positive returns. Nature Rev. Drug Discov. 8, 609–610 (2009).

Helpman, E. & Trajtenberg, M. in General Purpose Technologies and Economic Growth (ed. Helpman, E.) 85–119 (The MIT Press, 1998).

Owen-Smith, J., Riccaboni, M., Pammolli, F. & Powell, W. A comparison of U.S. & European university–industry relations in the life sciences. Manage. Sci. 48, 24–43 (2002). An in-depth comparative analysis of the US and European systems of innovation in the life sciences.

Braunwald, E. et al. Harrison's Principle of Internal Medicine 15th edn (McGraw-Hill, 2001).

Abrantes-Metz, R., Adams, C. & Metz, A. Pharmaceutical development phases: a duration analysis. J. Pharma. Fin. Econ. Policy 14, 19–41 (2006).

Adams, C. & Van Brantner, V. Estimating the cost of new drug development: is it really $802 million? Health Affairs 25, 420–428 (2006).

DiMasi, J. & Faden, L. Factors associated with multiple FDA review cycles and approval phase times. Drug Inform. J. 43, 201–225 (2009).

Keyhani, S., Diener-West, M. & Powe, N. Are development times for pharmaceuticals increasing or decreasing? Health Affairs 25, 461–468 (2006).

Ma, P. & Zemmel, R. Value of novelty? Nature Rev. Drug Discov. 1, 571–572 (2002).

Yin, W. Market incentives and pharmaceutical innovation. J. Health Econ. 27, 1060–1077 (2008).

Coté, T., Kelkar, A., Xu, K., Braun, M. M. & Phillips M. I. Orphan products: an emerging trend in drug approvals. Nature Rev. Drug Discov. 9, 84 (2010).

Trusheim, M. R., Berndt, E. R. & Douglas, F. L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nature Rev. Drug Discov. 6, 287–293 (2007).

DiMasi, J. & Grabowski, H. G. Economics of new oncology drug development. J. Clin. Oncol. 25, 209–216 (2007).

Acemoglu, D. & Lin, J. Market size in innovation: theory and evidence from the pharmaceutical industry. Q. J. Econ. 119, 1049–1090 (2003).

Kneller, R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nature Rev. Drug Discov. 9, 867–882 (2010).

Grabowski, H. G. & Wang, Y. R. The quantity and quality of worldwide new drug introductions, 1982–2003. Health Affairs 25, 452–460 (2006).

Friedman, Y. Location of pharmaceutical innovation: 2000–2009. Nature Rev. Drug Discov. 9, 835–836 (2010).

Light, D. Global drug discovery: Europe is ahead. Health Affairs 28, W969–W977 (2009).

Cohen, W., Nelson, R. & Walsh, J. Protecting their intellectual assets: appropriability conditions and why U.S. manufacturing firms patent (or not). NBER Working Paper No. 7552 (National Bureau of Economic Research, 2000).

Henderson, R. & Cockburn, I. Scale, scope, and spillovers: the determinants of research productivity in drug discovery. Rand. J. Econ. 27, 32–59 (1996).

Arora, A., Gambardella, A., Pammolli, F. & Riccaboni, M. in Innovation and Competitiveness in the European Chemical Industry (eds Cesaroni, F., Gambardella, A. & Garcia-Fontes, W.) 175–202 (Springer, 2004).

Arora, A., Gambardella, A., Magazzini, L. & Pammolli, F. A breath of fresh air? Firm type, scale, scope and selection effects in drug development. Manage. Science 55, 1638–1653 (2009).

Danzon, P. M. & Chao, L. W. Cross-national price differences for pharmaceuticals: how large, and why? J. Health Econ. 19, 159–196 (2000).

Drews, J. Drug discovery: a historical perspective. Science 287, 1960–1964 (2000).

Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727–730 (2002).

Drews, J. Strategic trends in the drug industry. Drug Discov. Today 8, 411–420 (2003).

Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How may drug targets are there? Nature Rev. Drug Discov. 5, 993–996 (2006).

Pammolli, F. & Riccaboni, M. Market structure and drug innovation. Health Affairs 23, 24–43 (2004).

Gambardella, A., Orsenigo, L. & Pammolli, F. Global Competitiveness in Pharmaceuticals: a European Perspective (Directorate General Enterprise of the European Commission, 2001).